

Investor Report

28 June 2024

Geiger Counter Limited

(the "Company")

Key Facts¹

Portfolio Managers	Keith Watson Robert Crayfourd			
Launch Date	July 2006			
Total Gross Assets	£100.3m			
Reference Currency	GBP			
Ordinary Shares	Net Asset Value: 62.97p Mid-Market Price: 49.50p			
Gearing	12.84%			
Premium / (Discount) to NAV	(21.39%)			
Ordinary Shares in Issue	152,669,347			
Annual Management Fee 1.38%				
Bloomberg	GCL LN			
Sedol	B15FW330			
Year End	30 September			
Contact Information	CQSClientServices@cq sm.com			
Company Broker	Cavendish Capital Markets Limited 020 7220 0500			
Annual Report and Accounts Published	December			
Investor Report	Monthly Factsheet			
Fiscal Year-End	30 September			
Results Announced	Finals: December Interims: June			

Sources: ¹R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. ²R&H Fund Services Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document. ³Market data sourced from Bloomberg unless otherwise stated. The Company may since have exited some or all of the positions detailed in the commentary. ⁴Source: World Nuclear Association as at June 2024 (https://world-nuclear-page activities/Nutricel. pall above abiff in

news.org/Articles/National-poll-shows-shift-in-Australian-nuclear-op; https://world-nuclear-news.org/Articles/US-support-for-nuclear-energy-at-record-high,-poll).





Keith Watson and Robert CrayfourdPortfolio Managers

Description

The objective of Geiger Counter Limited is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium industry. Up to 30% of the value of the Company's investment portfolio may be invested in other resource-related companies from outside the energy sector.

Key Advantages for the Investor

- · Access to mining assets in the uranium sector
- May benefit from embedded subscription share
- Low correlation to major asset classes

Ordinary Share and NAV Performance²

	1 Month (%)	3 Months (%)	1 Year (%)	3 Years (%)	5 Years (%)
NAV	(13.19)	(11.68)	42.56	63.26	229.17
Share Price	(6.07)	(1.00)	33.78	27.25	161.90

Commentary³

In June the price of U3O8 (uranium oxide) decreased by 3%, finishing the month at \$85.5/lb. Amid this backdrop, uranium equities showed pronounced weakness. The Company's NAV declined by 13.2%, closely mirroring the 12.8% drop in the Sprott Uranium Miners ETF (in sterling terms) and the 9.8% decline of the Solactive Uranium Pure Play Index. Even physically-backed uranium vehicles underperformed the uranium price with both Sprott Physical Uranium Trust and Yellow Cake experiencing share price declines of 10% over the month.

Sentiment remained subdued despite favourable steps being taken to support the industry. Notably, following legislation signed into law in May, the US announced a \$2.7 billion package to finance the purchase of domestically enriched uranium, aiming to encourage investment within the country. This initiative should accelerate the pick-up in utility buying of US origin material, which held a limited 5% share in 2023.

Elsewhere, the newly installed military government in Niger revoked the uranium mining licenses of France's state-owned Orano, which was in the process of resuming development of the Imouraren project. While this may stall future output from the proposed mine, it also raises the possibility of similar decisions affecting Orano's operating mine. Niger appears to be strengthening ties with Russia, with Rosatom potentially in line to be awarded licenses in the country. Although Niger's share of uranium production has been declining, this action will further encourage Western buyers to source supply from less risky jurisdictions.

Meanwhile, in the background, public opinion towards the sector in western markets continues to improve. Recent surveys undertaken in the US and Australia show growing support for the industry, a process which we believe will further encourage political momentum for wider inclusion of nuclear energy - particularly in Australia which has banned nuclear power generation since 1998. This public opinion may also lead to a reconsideration of the current prohibition on uranium mining in US states, such as Virginia, and in Western Australia. This could benefit companies such as IsoEnergy and Laramide that own assets in these locations.

Nexgen announced that the Canadian Nuclear Safety Commission had accepted their responses to the remaining technical review comments on the revised Federal EIS development of the Rook I project in the Athabasca Basin. This allows for a final 60-day technical review ahead of the hearing process. Cost inflation, together with the incorporation of incremental water management costs, is mooted to increase capital expenditures up to CAD\$2bn, an increase from the CAD\$1.3bn estimated in the 2021 feasibility study. Much of this news appears to have been digested and the shares performed in line with the broader sector. A revised economic update is expected later this year.



Commentary¹

Despite the US' move to fund uranium purchases, projects in the region were derated over the month. Ur-Energy is currently ramping up production, and the Geiger Counter has increased its exposure towards the end of the month. We expect progress to continue, although the ramp-up is currently slower than anticipated.

During the month, ASX-listed Paladin made an all-share offer for Fission Uranium at a near 30% premium. This boosted the latter's shares, which rose 17% on the announcement and closed the month 3% higher with a potentially enlarged holding, assuming the deal is completed. The Company reduced the position in Paladin, which closed the month around 20% lower.

AIFMD Leverage Limit Report (% NAV)

	Gross Leverage (%) ²	Commitment Leverage (%) ³
Geiger Counter Limited	113	113

Top 5 Holdings (%)4

Name	(% of Gross Assets)
Nexgen Energy	23.8%
UR-Energy	11.3%
Cameco	9.3%
Paladin Energy	8.0%
Uranium Energy	7.5%
Top 5 Holdings Represent	60.0

The Company has announced the fourth Subscription Rights Price of 74.58 pence on 1 May 2024. The exercise date for the fourth Subscription Right is expected to be 30 April 2025.

Sources: ¹Market data sourced from Bloomberg unless otherwise stated. The Company may since have exited some or all of the positions detailed in the commentary. ²Manulife | CQS Investment Management, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 7, 9 and 10 of Delegated Regulation 231/2013. ³Manulife | CQS Investment Management, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 8, 9, 10 and 11 of Delegated Regulation 231/2013. ⁴R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. All holdings data are rounded to one decimal place. Total may differ to sum of constituents due to rounding.



Important Information

Manulife | CQS Investment Management is a trading name of CQS (UK) LLP which is authorised and regulated by the Financial Conduct Authority. This document has been issued by CQS (UK) LLP and/or CQS (US), LLC which is a registered investment adviser with the US Securities and Exchange Commission, The term "CQS" or "Manulife | CQS Investment Management" as used herein may include one or more of CQS (UK) LLP, CQS (US), LLC or any other affiliated entity. The information is intended solely for sophisticated investors who are (a) professional investors as defined in Article 4 of the European Directive 2011/61/EU or (b) accredited investors (within the meaning given to such term in Regulation D under the U.S. Securities Act of 1933, as amended) and qualified purchasers (within the meaning given to such term in Section 2(a)(51) of the U.S Investment Company Act 1940, as amended). This document is not intended for distribution to, or use by, the public or any person or entity in any jurisdiction where such use is prohibited by law or regulation.

Manulife | CQS Investment Management is a wholly owned subsidiary of Manulife Investment Management (Europe) Limited.

This document is a marketing communication prepared for general information purposes only and has not been delivered for registration in any jurisdiction nor has its content been reviewed by any regulatory authority in any jurisdiction. The information contained herein does not constitute: (i) a binding legal agreement; (ii) legal, regulatory, tax, accounting or other advice; (iii) an offer, recommendation or solicitation to buy or sell shares or interests in any fund or investment vehicle managed or advised by CQS (a "CQS Fund") or any other security, commodity, financial instrument, or derivative; or (iv) an offer to enter into any other transaction whatsoever (each a "Transaction"). Any decision to enter into a Transaction should be based on your own independent investigation of the Transaction and appraisal of the risks, benefits and appropriateness of such Transaction in light of your circumstances. Any decision to enter into any Transaction should be based on the terms described in the relevant offering memorandum, prospectus or similar offering document, subscription document, key investor information document (where applicable), and constitutional documents and/or any other relevant document as appropriate (together, the "Offering Documents"). Any Transaction will be subject to the terms set out in the Offering Documents and all applicable laws and regulations. The Offering Documents supersede this document and any information contained herein. The Offering Documents for CQS UCITS range of funds is available here (https://www.cqs.com/ucits-funds#global-convertibles) in English (US persons will not be eligible to invest in CQS managed UCITS funds save to the extent set out in the relevant Offering Document). A copy of CQS' Complaints Policy, which sets out a summary of investors' rights, is available here (www.cqs.com/site-services/regulatory-disclosures) in English. CQS may terminate the arrangements for marketing or distribution of any CQS Fund at any time.

Nothing contained herein shall give rise to a partnership, joint venture or any fiduciary or equitable duties. The information contained herein is provided on a non-reliance basis, not warranted as to completeness or accuracy, and is subject to change without notice. Any information contained herein relating to any non-affiliated third party is the sole responsibility of such third party and has not been independently verified by CQS. The accuracy of data from third party vendors is not guaranteed. If such information is not

accurate, some of the conclusions reached or statements made may be adversely affected. CQS is not liable for any decisions made or action taken by you or others based on the contents of this document and neither CQS nor any of its directors, officers, employees or representatives accept any liability whatsoever for any errors or omissions or any loss howsoever arising from the use of this document.

Information contained in this document should not be viewed as indicative of future results as past performance of any Transaction is not indicative of future results. Any investment in a CQS Fund or any of its affiliates involves a high degree of risk, including the risk of loss of the entire amount invested. The value of investments can go down as well as up. Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. Investments may lead to a financial loss if no guarantee on the capital is in place. An investment in any CQS Fund will involve a number of material risks which include, without limitation, risks associated with adverse market developments, currency and exchange rate risks, risk of counterparty or issuer default, and risk of illiquidity. Any assumptions, assessments, targets (including target returns and volatility targets), statements or other such views expressed herein (collectively "Statements") regarding future events and circumstances or that are forward looking in nature constitute CQS' subjective views or beliefs and involve inherent risk and uncertainties beyond CQS' control. Any indices included in this document are for illustrative purposes only and are not representative of CQS Funds in terms of either composition or risk (including volatility and other risk related factors). Unless stated to the contrary CQS Funds are not managed to a specific index.

The information contained herein is confidential and may be legally privileged and is intended for the exclusive use of the intended recipient(s) to which the document has been provided. In accepting receipt of the information transmitted you agree that you and/or your affiliates, partners, directors, officers and employees, as applicable, will keep all information strictly confidential. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information is prohibited. Any distribution or reproduction of this document is not authorized and prohibited without the express written consent of CQS, or any of its affiliates. Unless otherwise stated to the contrary herein, CQS owns all intellectual property rights in this document.

PRI Note:

PRI is an investor initiative in partnership with UNEP Finance and the UN Global Compact. GMv12.

G1220624/ 06.24

CQS (UK) LLP

4th Floor, One Strand, London WC2N 5HR, United Kingdom *T*: +44 (0) 20 7201 6900 | *F*: +44 (0) 20 7201 1200

CQS (US), LLC

152 West 57th Street, 40th Floor, New York, NY 10019, US *T*: +1 212 259 2900 | *F*: +1 212 259 2699





















